Endogenous cortisol 6β-hydroxylation clearance is not an accurate probe for overall cytochrome P450 3A phenotyping in humans

Clinica Chimica Acta

Volumn 408, Issue 1-2, 2009, Pages 92-97

  Hu, Zhe Yi ^a   Zhao, Yuan Sheng ^a   Wu, Di ^b   Cheng, Ze Neng ^c  

^a SHANGHAI INSTITUTE OF MATERIA MEDICA   (China)

^b CHILDREN S HOSPITAL OF PHILADELPHIA   (United States)

^c CENTRAL SOUTH UNIVERSITY   (China)

Author keywords

6 hydroxycortisol; Cortisol; CYP3A; Midazolam

Indexed keywords

6BETA HYDROXYHYDROCORTISONE; ALPHA HYDROXYMIDAZOLAM; CYTOCHROME P450 3A; HYDROCORTISONE; MIDAZOLAM;

ACCURACY; ADULT; AREA UNDER THE CURVE; ARTICLE; CONTROLLED STUDY; DRUG BLOOD LEVEL; DRUG CLEARANCE; DRUG URINE LEVEL; FEMALE; GENETIC VARIABILITY; HALF LIFE TIME; HIGH PERFORMANCE LIQUID CHROMATOGRAPHY; HUMAN; HYDROCORTISONE BLOOD LEVEL; HYDROCORTISONE URINE LEVEL; MALE; MAXIMUM PLASMA CONCENTRATION; MEAN RESIDENCE TIME; NORMAL HUMAN; PHENOTYPE; PRIORITY JOURNAL; QUANTITATIVE ANALYSIS; TIME TO MAXIMUM PLASMA CONCENTRATION;

ADMINISTRATION, ORAL; CYTOCHROME P-450 CYP3A; FEMALE; HUMANS; HYDROCORTISONE; HYDROXYLATION; MALE; MIDAZOLAM; PHENOTYPE; TIME FACTORS;

EID: 69849094943     PISSN: 00098981     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.cca.2009.07.017     Document Type: Article

References (29)

1. Streetman D.S., Bertino Jr. J.S., and Nafziger A.N. Phenotyping of drug-metabolizing enzymes in adults: a review of in-vivo cytochrome P450 phenotyping probes. Pharmacogenetics 10 (2000) 187-216
2. Krishna D.R., and Shekar M.S. Cytochrome P450 3A: genetic polymorphisms and inter-ethnic differences. Methods Find Exp Clin Pharmacol 27 (2005) 559-567
3. Dahl M.L. Cytochrome P450 phenotyping/genotyping in patients receiving antipsychotics: useful aid to prescribing?. Clin Pharmacokinet 41 (2002) 453-470
4. Zaigler M., Tantcheva-Poor I., and Fuhr U. Problems and perspectives of phenotyping for drug-metabolizing enzymes in man. Int J Clin Pharmacol Ther 37 (2000) 1-9
5. Lu A.Y., Wang R.W., and Lin J.H. Cytochrome P450 in vitro reaction phenotyping: a re-evaluation of approaches used for P450 isoform identification. Drug Metab Dispos 31 (2003) 345-350
6. Thummel K.E., Shen D.D., Podoll T.D., et al. Use of midazolam as a human cytochrome P450 3A probe: I. in vitro-in vivo correlations in liver transplant patients. J Pharmacol Exp Ther 271 (1994) 549-556
7. Thummel K.E., Shen D.D., Podoll T.D., et al. Use of midazolam as a human cytochrome P450 3A probe: II. Characterization of inter- and intraindividual hepatic CYP3A variability after liver transplantation. J Pharmacol Exp Ther 271 (1994) 557-566
8. Krupka E., Venisse N., Lafay C., et al. Probe of CYP3A by a single-point blood measurement after oral administration of midazolam in healthy elderly volunteers. Eur J Clin Pharmacol 62 (2006) 653-659
9. Zhu B., Ou-Yang D.S., Cheng Z.N., Huang S.L., and Zhou H.H. Single plasma sampling to predict oral clearance of CYP3A probe midazolam. Acta Pharmacol Sin 22 (2001) 634-638
10. Lee L.S., Bertino Jr. J.S., and Nafziger A.N. Limited sampling models for oral midazolam: midazolam plasma concentrations, not the ratio of 1-hydroxymidazolam to midazolam plasma concentrations, accurately predicts AUC as a biomarker of CYP3A activity. J Clin Pharmacol 46 (2006) 229-234
11. Kim J.S., Nafziger A.N., Tsunoda S.M., et al. Limited sampling strategy to predict AUC of the CYP3A phenotyping probe midazolam in adults: application to various assay techniques. J Clin Pharmacol 42 (2002) 376-382
12. Lin Y.S., Lockwood G.F., Graham M.A., et al. In-vivo phenotyping for CYP3A by a single-point determination of midazolam plasma concentration. Pharmacogenetics 11 (2001) 781-791
13. Eap C.B., Buclin B., Cucchia G., et al. Oral administration of a low dose of midazolam (75μg) as an in vivo probe for CYP3A activity. Eur J Clin Pharmacol 60 (2004) 237-246
14. Galteau M.M., and Shamsa F. Urinary 6β-hydroxycortisol: a validated test for evaluating drug induction or drug inhibition mediated through CYP3A in humans and in animals. Eur J Clin Pharmacol 59 (2003) 713-733
15. Hunt C.M., Watkins P.B., Saenger P., et al. Heterogeneity of CYP3A isoforms metabolizing erythromycin and cortisol. Clin Pharmacol Ther 51 (1992) 18-23
16. Watkins P.B., Turgeon D.K., Saenger P., et al. Comparison of urinary 6-β-cortisol and the erythromycin breath test as measures of hepatic P450IIIA (CYP3A) activity. Clin Pharmacol Ther 52 (1992) 265-273
17. Kinirons M.T., O'Shea D., Downing T.E., et al. Absence of correlations among three putative in vivo probes of human cytochrome P4503A activity in young healthy men. Clin Pharmacol Ther 54 (1993) 621-629
18. Kinirons M.T., O'Shea D., Kim R.B., et al. Failure of erythromycin breath test to correlate with midazolam clearance as a probe of cytochrome P4503A. Clin Pharmacol Ther 66 (1999) 224-231
19. Furuta T., Suzuki A., Mori C., Shibasaki H., Yokokawa A., and Kasuya Y. Evidence for the validity of cortisol 6β-hydroxylation clearance as a new index for in vivo cytochrome P450 3A phenotyping in humans. Drug Metab Dispos 31 (2003) 1283-1287
20. Hu Z., Gong Q., Hu X., et al. Simultaneous determination of 6β-hydroxycortisol and cortisol in human urine and plasma by liquid chromatography with ultraviolet absorbance detection for phenotyping the CYP3A activity. J Chromatogr B 826 (2005) 238-243
21. Yasui-Furukori N., Inoue Y., and Tateishi T. Sensitive determination of midazolam and 1'-hydroxymidazolam in plasma by liquid-liquid extraction and column-switching liquid chromatography with ultraviolet absorbance detection and its application for measuring CYP3A activity. J Chromatogr B 811 (2004) 153-157
22. Chen Y.C., Gotzkowsky S.K., Nafziger A.N., et al. Poor correlation between 6β-hydroxycortisol:cortisol molar ratios and midazolam clearance as measure of hepatic CYP3A activity. Br J Clin Pharmacol 62 (2006) 187-195
23. Eeckhoudt S.L., Desager J.P., Robert A.R., Leclercq I., Verbeeck R.K., and Horsmans Y. Midazolam and cortisol metabolism before and after CYP3A induction in humans. Int J Clin Pharmacol Ther 39 (2001) 293-299
24. Ueda K., Okumura N., Hirai M., et al. Human P-glycoprotein transports cortisol, aldosterone, and dexamethazone, but not progesterone. J Biol Chem 267 (1992) 24248-24252
25. Tolle-Sander S., Rautio J., Wring S., Polli J.W., and Polli J.E. Midazolam exhibits characteristics of a highly permeable P-glycoprotein substrate. Pharm Res 20 (2003) 757-764
26. Masica A.L., Mayo G., and Wilkinson G.R. In vivo comparisons of constitutive cytochrome P450 3A activity assessed by alprazolam, triazolam, and midazolam. Clin Pharmacol Ther 76 (2004) 341-349
27. Cummins C.L., Wu C.Y., and Benet L.Z. Sex-related differences in the clearance of cytochrome P450 3A4 substrates may be caused by P-glycoprotein. Clin Pharmacol Ther 72 (2002) 474-489
28. Schuetz E.G., Furuya K.N., and Schuetz J.D. Interindividual variation in expression of P-glycoprotein in normal human liver and secondary hepatic neoplasms. J Pharmacol Exp Ther 275 (1995) 1011-1018
29. Gorski J.C., Jones D.R., Haehner-Daniels B.D., Hamman M.A., O'Mara Jr. E.M., and Hall S.D. The contribution of intestinal and hepatic CYP3A to the interaction between midazolam and clarithromycin. Clin Pharmacol Ther 64 (1998) 133-143